Finally, it is of interest the fact that there was no association of poor prognostic cytogenetic abnormalities and of additional gene mutations in myeloid genes, MDS-related genes and in KRAS/NRAS with the patient outcomes. The gene discussed is KRAS; the disease is myelodysplastic syndrome.